Endotrophin and C6Ma3, Serological Biomarkers of Type VI Collagen Remodeling, Reflect Endoscopic and Clinical Disease Activity in IBD

Scientists investigated if remodeling of the intestinal basement membrane type VI collagen was associated with pathophysiological changes in Crohn’s disease and ulcerative colitis.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

Share

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ – New Innovative Treatment for Irritable Bowel Syndrome with Constipation

Knight Therapeutics, Inc. announced the Canadian commercial availability of IBSRELA, a first-in-class therapy for the treatment of IBS with constipation in adults.
[Knight Therapeutics Inc.]
Press Release
Bookmark

No account yet? Register

Share

Local Immune Response to Food Antigens Drives Meal-Induced Abdominal Pain

Scientists showed that a bacterial infection and bacterial toxins could trigger an immune response that led to the production of dietary-antigen-specific IgE antibodies in mice, which were limited to the intestine.
[Nature]
Aguilera-Lizarraga, J., Florens, M. V., Viola, M. F., Jain, P., Decraecker, L., Appeltans, I., Cuende-Estevez, M., Fabre, N., Van Beek, K., Perna, E., Balemans, D., Stakenborg, N., Theofanous, S., Bosmans, G., Mondelaers, S. U., Matteoli, G., Ibiza Martínez, S., Lopez-Lopez, C., Jaramillo-Polanco, J., … Boeckxstaens, G. E. (2021). Local immune response to food antigens drives meal-induced abdominal pain. Nature, 1–6. https://doi.org/10.1038/s41586-020-03118-2 Cite
Abstract
Bookmark

No account yet? Register

Share

FDA Authorizes New IND to Evaluate Impact of Multi-Strain Probiotic DS-01TMon Gut Microbiota of Patients with IBS

The regulatory acceptance enables a team of gastroenterologists at Beth Israel Deaconess Medical Center to initiate a Phase II randomized, triple-blind, and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome, as well as the impact of DS-01™ on both intestinal cells and metabolic output of the native intestinal microbial communities.
[Seed Health Inc. (PRNews]
Press Release
Bookmark

No account yet? Register

Share

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase I Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc.announced dosing of the first healthy volunteer in the company’s phase I clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function.
[Immunic Therapeutics Inc.]
Press Release
Bookmark

No account yet? Register

Share

Acute Stress Disrupts Intestinal Homeostasis via GDNF-RET

In vitro, glial cell‐derived neurotrophic factor (GDNF) treatment amplified Wnt signal and increased serotonin levels in colonic organoids in a dose‐dependent manner.
[Cell Proliferation]
Lin, L., Feng, B., Zhou, R., Liu, Y., Li, L., Wang, K., Yu, Y., Liu, C., Long, X., Gu, X., Li, B., Wang, X., Yang, X., Cong, Y., Zuo, X., & Li, Y. (n.d.). Acute stress disrupts intestinal homeostasis via GDNF-RET. Cell Proliferation, n/a(n/a), e12889. https://doi.org/10.1111/cpr.12889 Cite
Full Article
Bookmark

No account yet? Register

Share

Role of Inflammation in Pathophysiology of Colonic Disease: An Update

The authors provide an update on the literature to understand how genetics, diet, and the gut microbiota influence the crosstalk between immune and non-immune cells resulting in inflammation observed in multiple colonic pathologies.
[International Journal of Molecular Sciences]
Full Article
Bookmark

No account yet? Register

Share
Share